ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY AGAINST DRUG-INDUCED ANTIGENS IN L5178Y MOUSE LYMPHOMA

P. FRANCO*, F. VERONESE*, F. LEVI*, A. GOLPIN† AND A. NICOLIN‡

From the *Institute of Pharmacology, School of Medicine, Via Vanvitelli 32, Milan, Italy, the †N.C.I., N.I.H., Bethesda, Md, U.S.A. and ‡Institute for Cancer Research, Genoa, Italy

Summary.—In vivo treatment with antineoplastic compounds has been reported to lead to the expression of new antigenic specificities which were not detected on parental cells, and which were transmissible as a genetic character. The current study is concerned with antibody-dependent cellular cytotoxic (ADCC) activity in serum of syngeneic mice challenged with LY/DTIC cells, a subline of LY murine lymphoma, antigenically altered by the drug DTIC. LY/DTIC target cells coated with LY/DTIC-immune serum were specifically lysed by virgin lymphocytes. The genetic background of the effector cells, whether syngeneic, allogeneic or xenogeneic, did not produce significant differences in the percentage of target-cell lysis. ADCC activity was reduced when the immune serum was added directly to the incubation medium, without precoating. Although sera from individual animals exhibited different levels of ADCC activity, they nevertheless followed the general trend of the pooled sera. Peak activity of ADCC was obtained in the sera collected on Days 8 and 30 after LY/DTIC cell challenge. The ADCC activity elicited by LY/DTIC cells may contribute to the rejection of drug-altered tumour cells.

In vivo treatment with antineoplastic drugs has been found to increase the antigenicity of mouse tumour cells (Melan et al., 1968; Mihich, 1969; Bonmassar et al., 1970; Nicolin et al., 1972, Fuji et al., 1973). These new antigenic specificities were not detected on parental cells, and were transmissible, as a genetic character, after the withdrawal of the drug (Nicolin et al., 1974). The pharmacologically induced antigenic alteration of tumour cells may lead to their rejection on inoculation into syngeneic hosts. An understanding of the immune reactivity to drug-induced antigens might lead to new methodologies for the experimental immunotherapy of murine neoplasms, designed to eradicate cancer cells totally (Oettgen, 1977). In a series of previous studies, drug-xenogenized tumour cells were found to elicit cellular rather than humoral immune responses (Testorelli et al., 1978; Fioretti et al., 1978). Antibodies specific to drug-induced antigens have been detected by a number of assays, including binding of radioiodinated immunoglobulin of hyperimmunized syngeneic animals (Kitano et al., 1972), a modified plaque assay (Fuji & Mihich, 1975) and direct, complement-dependent cytotoxicity (Nicolin et al., 1976a). In these studies, the activity, though specific and reproducible, was generally not extensive. In the present study, the serum of mice challenged with L5178Y lymphoma cells antigenically altered by treatment with the anticancer drug 5(3,3-dimethyl triazeno) imidazole-4-carboxamide (DTIC) was used to determine the extent of antibody-dependent cellular cytotoxicity (ADCC) against the DTIC-altered tumour cells.
MATERIALS AND METHODS

Animals and tumours.—Three-month-old inbred DBA/2Cr, BALB/c, C57BL/6J, C3H male mice, hybrid (BALB/c x DBA/2Cr) F1 male mice, hereafter called CD2F1, obtained from the Charles River Breeding Laboratories, Calco, Italy, and 12–15 week-old Sprague-Dawley male rats obtained from Farmitalia-Carlo Erba, Milan, Italy, were used in the experiments. L5178Y lymphoma (LY) chemically induced in DBA/2 mice (kindly supplied by Dr. P. Alexander, Sutton, England) was maintained by weekly i.p. passages in compatible animals. The LY/DTIC subline was obtained by daily in vitro treatment of the parental LY lymphoma with DTIC (100 mg/kg i.p.) for 5 transplant generations, as previously described (Nicolin et al., 1976b), and maintained by in vivo passages in CD2F1 mice that had been immunosuppressed with cyclophosphamide (200 mg/kg i.p.) 24 h before tumour inoculation.

Drugs.—DTIC (NSC-45388) was dissolved in chilled saline after addition of equal parts (v/w) of citric acid. Cyclophosphamide (NSC-26271) was dissolved in saline immediately before use. Both drugs were obtained through the courtesy of Dr. V. L. Narayanan, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, U.S.A.

Immune sera.—CD2F1 mice were immunized against LY/DTIC tumour cells by i.p. challenge with 10^7 viable cells or to LY tumour cells by i.p. challenge of 2 x 10^7 irradiated cells (Securix Compact machine; 50 Gy 200 kV, 12 mA, 0.5 mm Cu-Al filter 1 Gy/min). Blood was obtained from the retro-orbital sinus at the time indicated, and sera were heat-inactivated at 56°C for 45 min before use. Hyperimmune sera were obtained by injecting 6 immunizations at 2-week intervals. In this case the first sensitization was s.c. with a 50:50 mixture (v/v) of cell suspension and complete Freund adjuvant.

ADCC assay.—The 51Cr-release microassay (Goldstein & Blomgren, 1973) was used. Target cells were LY or LY/DTIC, pre-labelled with Na_2 51CrO_4 (Amersham) 200 μCi/10^7 cells, and effector cells were spleen cells from virgin animals or circulating lymphocytes from healthy donors. 51Cr-labelled target cells (10^5) in a volume of 100 μl, pre-incubated with serial dilutions of the serum, were seeded in V-bottomed microplates (Sterilin, Teddington, Middlesex) with 100 μl of different ratios of effector cells and incubated 4 h at 37°C in a moist atmosphere of 95% air and 5% CO_2. Alternatively, target cells and effector cells, in 100 μl final volume, were incubated 4 h in the presence of 100 μl of serum. The plates were centrifuged and 100 μl supernatant was counted in an automatic gamma counter.

The ADCC activity was expressed as percentage of cytotoxicity as follows:

\[
\text{Specific cytotoxicity} = \frac{\text{ct/min in experimental samples} - \text{ct/min in controls}^*}{\text{ct/min in detergent samples} - \text{ct/min in controls}} \times 100
\]

RESULTS

Serum of animals challenged with a single inoculum of 10 x 10^6 viable LY/DTIC cells did not exhibit complement-dependent cytotoxicity, but lytic antibodies were obtained after extensive sensitization with LY/DTIC tumour cells. In that case, however, specific 51Cr release did not exceed that of the controls by more than 20%, and diminished rapidly on dilution (Fig. 1). Parental LY target cells were not lysed by anti-LY/DTIC serum and guinea-pig complement, nor were either cell types lysed by sera obtained in syngeneic animals by several injections of X-inactivated LY cells.

LY/DTIC target cells, coated with serum from animals challenged with 10 x 10^6 viable LY/DTIC cells, were lysed by virgin, syngeneic lymphocytes (Fig. 2). High and biphasic ADCC activity was obtained. A peak of target-cell lysis (about 50%) was detected at a serum dilution of 1/64, and a second peak was seen at a dilution of 1/512. A “prozone” effect, reduced ADCC activity at the

*Controls were labelled target cells incubated with normal mouse serum and spleen cells from virgin animals. Detergent for the maximum-release determination was a 5% water solution of Brij 35 (BDH, Milan, Italy).
highest serum concentrations, as reported by other authors in different tumour systems, and a fall of activity at serum dilutions between 1/64 and 1/512 were seen. Lysis did not occur with LY target cells or unrelated target cells, nor were X-ray-inactivated parental LY cells injected in CD2F1 mice did not elicit serum effective in the complement-dependent lysis, 1:5 rabbit serum pre-adsorbed on mouse liver cells was the source of complement.

Fig. 1.—Complement-dependent lytic activity of anti-LY/DTIC serum. $^{51}$Cr-labelled LY/DTIC cells (○), or $^{51}$Cr-labelled LY cells (●), were incubated with immune serum to LY/DTIC cells (---), hyper-immune serum to LYDTIC (——) and normal serum (----) in the presence of complement. X-ray-inactivated parental LY cells injected in CD2F1 mice did not elicit serum effective in the complement-dependent lysis, 1:5 rabbit serum pre-adsorbed on mouse liver cells was the source of complement.

was obtained at a lower dilution (1/32). The specificity was mediated by anti-LY/DTIC antibodies, while unprimed cells from different species have been the Fe$^+$ populations, antibody-dependent for cell lysis. Anti-LY serum did not show ADCC activity in the assay with allogeneic or xenogeneic lymphocytes (data not reported here). The kinetics of antibody production after challenge with LY/DTIC cells is reported in Fig. 5. With syngeneic or allogeneic effector cells, two peaks of activity were observed: a narrow peak on Day 8 after the immunizing inoculum, and a second, broad peak around the 30th day. Maximum activity was obtained on Day 8 with syngeneic effectors, and on Day 30 with allogeneic lymphocytes. Comparison of the differences in activity is not possible, since target cells were coated with serum diluted 1/64 or 1/32, depending on whether the effector system was syngeneic or allogeneic. Fig. 6 shows the ADCC activity of serum from individual animals. Target cells coated with serum from CD2F1 mice challenged with $10 \times 10^6$ LY/DTIC cells i.p. showed differences in susceptibility to lysis by C57BL/6J lymphocytes. Despite the individual variability of the sera in mediating in vitro ADCC, the pattern of the activity was similar to that observed with pooled sera.

**DISCUSSION**

It is well established that target-cell destruction can be mediated through different immunological mechanisms (Cerottini & Brunner, 1977). Specific cellular lysis of tumour cell is mainly performed by the classic T-cell immunity mechanism (Cerottini & Brunner, 1974) or the interaction of antibody with normal lymphoid cells, the latter being referred to as antibody-dependent cellular cytotoxicity (ADCC). The precise mechanism of ADCC is not understood, though it is known that the specificity of this immunological reaction is determined by antibody bound to membrane-associated
antigens, and that the effector cells bear receptors for the F\textsubscript{c} fragment of the immunoglobulin molecules (Greenberg \textit{et al.}, 1975), but the effector cells lack both T- and B-cell characteristics.

Little is known about the \textit{in vivo} significance of ADCC, which was identified by means of \textit{in vitro} experiments, both in human and animal systems. ADCC has been demonstrated against cells infected with a variety of viruses (Lamon \textit{et al.}, 1976; Shore \textit{et al.}, 1976a) and also against
ADCC IN L5178Y/DTIC MOUSE LYMPHOMA

Fig. 4.—Lysis of antibody-coated LY/DTIC cells by xenogeneic or allogeneic effector cells. Effector cells were spleen cells from 3 outbred Sprague–Dawley rats (○), C57BL/6J mice (●), C3H (□) or BALB/c mice (△). Serum was obtained from CD2F1 mice 30 days after their sensitization with 10 x 10⁶ LY/DTIC cells. Target cells were ⁵¹Cr-labelled LY/DTIC cells.

Fig. 5.—Kinetics of serum activity in the ADCC assay after sensitization with 10 x 10⁶ viable LY/DTIC cells. Effector cells were splenic lymphocytes from 3 syngeneic CD2F1 mice (○—○) or from 3 allogeneic C57BL/6J mice (●—●). Serum dilutions were 1:64 for CD2F1 or 1:32 for C57BL/6J, respectively. Target cells were ⁵¹Cr-labelled LY/DTIC cells.

tumour-associated antigens (Wunderlich et al., 1975; Durantez & Zighelboim, 1976), histocompatibility (Yust et al., 1974; Jeannet & Vassalli, 1976) or auto-antigens (Feldmann et al., 1976). It would appear that any cell in which a virus is replicating has altered membrane properties which make that cell susceptible to destruction by this mechanism (Shore et al., 1976b). This would also hold true for tumour cells or cells expressing new or altered membrane antigens, if they are strong enough to evoke an immune response.

Even though the role of ADCC in vivo and its potential participation in immunosurveillance has still to be defined, the high sensitivity of this in vitro assay for detecting low amounts of antibody can have several applications (Trinchieri et al., 1973; Zighelboim et al., 1974a, b).

In the present study, a high level of ADCC activity was shown by serum from animals immunized with LY/DTIC cells. Serum from animals sensitized only once
with LY/DTIC cells mediated high ADCC activity (~50% cell lysis) in contrast with no activity in the direct, complement-dependent assay.

Complement-dependent humoral cytotoxicity could be detected (never above 20% specific 51Cr release) in the serum of animals only after multiple immunizations, and the activity was lost at serum dilutions effective in mediating ADCC. The activity mediated by the sera raised in syngeneic animals immunized with LY/DTIC cells was similar to that mediated by sera from animals bearing highly immunogenic tumours or challenged with histoincompatible cells (Blair et al., 1976).

The current observations with DTIC-induced antigens are consistent with previous studies with other transplantation antigens (de Landazuri et al., 1974; Berger & Amos, 1977) in that the cytotoxic antibody synthesis was very low, in contrast with the marked synthesis of binding antibodies effective in the ADCC assay.

Although the molecular nature of these antigens has not yet been studied, our data may contribute to an understanding of their biological characteristics and to a definition of their immunological properties.

The authors acknowledge the kind assistance of Dr J. Mayo and C. Reeder, Mammalian Genetics and Animal Production Section, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, for breeding and providing the animals. The proficient help of D. Feroli and C. De Carpegna is gratefully acknowledged.

This research was supported in part by PFCCN from C.N.R., Rome, Italy.

REFERENCES

Berger, A. E. & Amos, D. B. (1977) A comparison of antibody dependent cellular cytotoxicity (ADCC) mediated by murine and human lymphoid cell populations. Cell. Immunol., 33, 277.

Blair, P. B., Lane, M. A. & Mar, P. (1976) Antibody in the sera of tumor bearing mice that mediate spleen cell cytotoxicity toward autologous tumour. J. Immunol., 116, 606.

Bonmassar, E., Bonmassar, A., Vadlamudi, S. & Goldin, A. (1970) Alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc. Natl Acad. Sci., 66, 1089.
ADCC IN L5178Y/DTIC MOUSE LYMPHOMA

CEROTTINI, J. & BRUNNER, T. (1974) Cell-mediated cytotoxicity, allograft rejection and tumor immunity. Adv. Immunol. 18, 67.

CEROTTINI, J. C. & BRUNNER, K. T. (1977) Mechanism of T and K cell-mediated cytosis, In B and T Cells in Immune Recognition (Ed. Loor & Roelants). London: John Wiley. p. 319.

DE LANDAZURI, H. O., KEDAR, E. & FAHEY, J. L. (1974) Synergistic cooperation between isoantiserum and immune lymphoid cells: In vitro studies with a syngeneic rat lymphoma. J. Immunol., 112, 2102.

DURANTEZ, A. & ZIGHELBOIM, J. (1976) Studies of lymphocyte-dependent antibodies to leukemia-associated antigens using frozen stored leukemia target cells. Transplantation, 22, 190.

FIELDMANN, J. L., BECKER, M. J., MOUTSOPoulos, H. & others (1976) Antibody-dependent-cell-mediated cytotoxicity in selected auto-immune diseases. J. Clin. Invest., 58, 173.

FIORIETTI, M. C., ROMANI, L., TARAMELLI, D. & GOLDIN, A. (1978) Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia. Transplantation, 26, 449.

FUJI, H., BERUACKI, R. & MIHICH, E. (1973) Increased immunogenicity and antigenicity of L1210 lymphomas resistant to antileukemic agent as measured in vitro. Fed. Proc., 32, 37.

FUJI, H. & MIHICH, E. (1976) Selection for high immunogenicity: Drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res., 35, 946.

GOLDSTEIN, P. & BLOMGREN, H. (1973) Further evidence for autonomy of T-cells mediating specific in vitro cytotoxicity: Efficiency of very small amounts of purified T-cells. Immunology, 9, 127.

GREENBERG, A. H., SHEN, L., WALKER, L., ARNAIZ-VILLENA, A. & ROIT, I. M. (1975) Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. II. The mouse nonadherent K cell. Eur. J. Immunol., 5, 474.

JEANNET, M. & VASSALLI, P. (1976) The role of lymphocyte-dependent antibody in kidney transplantation. Transplantation, 22, 493.

KITANO, M., MIHICH, E. & PRESSMAN, D. (1972) Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis (guanyl-hydrazone). Cancer Res., 32, 181.

LAMON, E. W., HALE, P. & WHITTEN, H. D. (1976) Antibody-dependent cell-mediated cytotoxicity with autochthonous lymphocytes and sera following Moloney sarcoma virus I infection. J. Natl Cancer Inst., 56, 349.

MELAN, F., NICOLIN, A. & TESTORELLI, C. (1968) Ricerche sulla possibilità di indurre alterazioni antigeniche in cellule tumorali mediante trattamento in vivo con chimioterapici. Arch. Ital. Patol. Clin. Tumori, 11, 203.

MIHICH, E. (1969) Modification of tumor regression by immunological means. Cancer Res., 29, 2345.

NICOLIN, A., VADLAMUDI, S. & GOLDIN, A. (1972) Antigenicity of L1210 leukemia sublines induced by drugs. Cancer Res., 32, 653.

NICOLIN, A., BINI, A., CORONELTI, E. & GOLDIN, A. (1974) Cellular immune response to a drug-treated L5178Y lymphoma subline. Nature, 251, 654.

NICOLIN, A., BINI, A., DI PADOVA, F. & GOLDIN, A. (1976a) Immunologic cross-reactivity of antigens(s) induced by drug treatment in two leukemic sublines. J. Immunol., 116, 1347.

NICOLIN, A., SPIRAFICO, F., BONMASSAR, E. & GOLDIN, A. (1976b) Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo. J. Natl Cancer Inst., 56, 89.

OETTGEN, H. F. (1977) Immunotherapy of cancer. N. Engl. J. Med., 297, 484.

SHORE, S. L., BLACK, C. M., MELEWIEZ, F. M., WOOD, P. A. & NAHMIAS, A. J. (1976a) Antibody-dependent cell-mediated cytotoxicity to target cells infected with Type 1 and Type 2 herpes simplex virus. J. Immunol., 118, 194.

SHORE, S. L., CROEMANS, T. L. & ROMANO, T. J. (1976b) Immune destruction of virus-infected cells early in the infectious cycle. Nature, 262, 695.

TESTORELLI, C., FRANCO, P., GOLDIN, A. & NICOLIN, A. (1978) In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas. Cancer Res., 38, 830.

TRINCHIERI, G., BERNOCCHI, D., CURTONI, S. E., MIGGIANO, C. & CEPPPELLINI, R. (1973) In Histocompatibility Testing Copenhagen: Munksgaard. p. 59

WUNDERLICH, J., ROSENBERG, E., CONNOLLY, J. & PARKS, J. (1975) Characteristics of a cytotoxic human lymphocyte-dependent antibody. J. Natl Cancer Inst., 54, 537.

YUST, L., WUNDERLICH, J. R., MANN, D. L. & TERRY, W. D. (1974) Identification of lymphocyte-dependent antibody in sera from multiply transfused patients. Transplantation, 18, 99.

ZIGHELBOIM, J., THIEME, T., GALE, R. P., OSSORIO, R. C. & FAHEY, J. L. (1974a) A sensitive method for detecting antibodies in human sera used for tissue typing, Transplantation, 18, 180.

ZIGHELBOIM, J., GALE, R. P., OSSORIO, R. C. & FAHEY, J. L. (1974b) A sensitive in vitro microassay for detecting antibody-dependent cellular cytotoxicity: Possible role in monitoring lymphocyte function. Transplantation, 18, 127.